Stay updated with breaking news from Jon Congleton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Greetings, and welcome to the Mineralys Second Quarter 2023 Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded.
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an...
Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)